<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01723618</url>
  </required_header>
  <id_info>
    <org_study_id>Cardoz-005</org_study_id>
    <nct_id>NCT01723618</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of CRD007 in Patients With Abdominal Aorta Aneurisms.</brief_title>
  <official_title>An Open-label, Randomised, Uncontrolled Trial Investigating the Pharmacokinetics of CRD007 After Single Dose Administration to Subjects With Abdominal Aortic Aneurysm (AAA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RSPR Pharma AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RSPR Pharma AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the plasma levels of CRD007 in patients with
      abdominal aortic aneurysms after the administration of single doses of tablets containing 10,
      25 and 40 mg CRD007.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics - maximum plasma concentration (Cmax)</measure>
    <time_frame>Pre-dose and until 12 hours post-dose</time_frame>
    <description>Plasma concentrations of CRD007 will be measured and standard pharmacokinetic parameters as Cmax will be measured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - time to maximum plasma concentration (tmax)</measure>
    <time_frame>Pre-dose til 12 hours post-dose</time_frame>
    <description>Plasma concentrations of CRD007 will be measured and standard pharmacokinetic parameters as tmax will be measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - Area under the plasma concentration curve (AUC)</measure>
    <time_frame>Pre-dose until 12 hours post-dose</time_frame>
    <description>Plasma concentrations of CRD007 will be measured and standard pharmacokinetic parameters as AUC will be measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics - elimination half life (t1/2)</measure>
    <time_frame>pre-dose until 12 hours post-dose</time_frame>
    <description>Plasma concentrations of CRD007 will be measured and standard pharmacokinetic parameters as t1/2 will be measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose linearity</measure>
    <time_frame>Pre-dose and until 12 hours post-dose</time_frame>
    <description>Evaluation of dose linearity in the dose range 10 - 40 mg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potential for accumulation</measure>
    <time_frame>Pre-dose untill 12 hours post-dose</time_frame>
    <description>To estimate the accumulation of CRD007 in the dose range 10 - 40 mg</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Abdominal Aortic Aneurisms</condition>
  <arm_group>
    <arm_group_label>CRD007 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRD007, 10 mg tablet, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRD007 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRD007, 25 mg tablet, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRD007 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CRD007, 40 mg tablet, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CRD007</intervention_name>
    <arm_group_label>CRD007 10 mg</arm_group_label>
    <arm_group_label>CRD007 25 mg</arm_group_label>
    <arm_group_label>CRD007 40 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infra-renal abdominal aortic aneurysm

        Exclusion Criteria:

          -  Significant concurrent disease or medical conditions that are deemed to interfere with
             the pharmacokinetics or the safety of CRD007 conduct of the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nikolaj F Groendal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Vascular Surgery Viborg Hospital Heiberg All√© 4 DK-8800 Viborg Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Vascular Surgery Viborg Hospital</name>
      <address>
        <city>Viborg</city>
        <zip>8800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2012</study_first_submitted>
  <study_first_submitted_qc>November 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2012</study_first_posted>
  <last_update_submitted>November 28, 2012</last_update_submitted>
  <last_update_submitted_qc>November 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm</mesh_term>
    <mesh_term>Aortic Aneurysm, Abdominal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

